drugset / Trial / NCT05176821
Eradication Efficacy and Safety of Two Rescue Treatments for Helicobacter Pylori Infection
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study was to evaluate the efficacy and safety of high-dose dual therapy compared with furazolidone-based quadruple therapy as a rescue treatment for helicobacter pylori infection.
Timeline
- Start
- 2021-01-01
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
Publications
- Background Yang J, Zhang Y, Fan L, Zhu YJ, Wang TY, Wang XW, Chen DF, Lan CH. Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori. Am J Gastroenterol. 2019 Mar;114(3):437-445. doi: 10.14309/ajg.0000000000000132.
- Background Yu L, Luo L, Long X, Liang X, Ji Y, Graham DY, Lu H. High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: A randomized trial. Helicobacter. 2019 Aug;24(4):e12596. doi: 10.1111/hel.12596. Epub 2019 May 20.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amoxicillin | Other / unclassified | 750 mg | — |
| Subject | Amoxicillin | Other / unclassified | 1000 mg | — |
| Comparator | Bismuth Potassium Citrate | Unknown | 600 mg | — |
| Comparator | Bismuth Potassium Citrate | Unknown | 1000 mg | — |
| Subject | Esomeprazole | Small molecule | 20 mg | — |
| Comparator | Furazolidone | Small molecule | 100 mg | — |